Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Aligos Therapeutics, Inc. - Common stock
(NQ:
ALGS
)
8.590
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 27, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aligos Therapeutics, Inc. - Common stock
< Previous
1
2
3
4
5
6
7
8
Next >
Aligos Therapeutics Presents Positive Data at the EASL Congress 2025
May 08, 2025
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results
May 06, 2025
From
Aligos Therapeutics
Via
GlobeNewswire
Earnings Scheduled For May 6, 2025
↗
May 06, 2025
Via
Benzinga
Aligos Therapeutics's Earnings Outlook
↗
May 05, 2025
Via
Benzinga
Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025
April 29, 2025
From
Aligos Therapeutics
Via
GlobeNewswire
How Is The Market Feeling About Aligos Therapeutics?
↗
January 14, 2025
Via
Benzinga
Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025
April 23, 2025
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Presents Positive Data at APASL 2025
March 26, 2025
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 14, 2025
From
Aligos Therapeutics
Via
GlobeNewswire
Monday's session: top gainers and losers
↗
March 10, 2025
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Via
Chartmill
Nasdaq, S&P 500 Hit 6-Month Lows As Recession Fears Grow: What's Driving Markets Monday?
↗
March 10, 2025
Stocks extended last week's losses on Monday as concerns over the U.S. economy continue to weigh on the market. The Nasdaq 100 saw the steepest declines, with Tesla, Inc. (NASDAQ:TSLA) and Palantir...
Via
Benzinga
Topics
Economy
Stocks
Let's uncover which stocks are experiencing notable gaps during today's session.
↗
March 10, 2025
The session on Monday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session.
Via
Chartmill
Top movers in Monday's pre-market session
↗
March 10, 2025
The US market is yet to commence its session on Monday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.
Via
Chartmill
Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2024 Financial Results
March 10, 2025
From
Aligos Therapeutics
Via
GlobeNewswire
Earnings Scheduled For March 10, 2025
↗
March 10, 2025
Via
Benzinga
Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025
March 03, 2025
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Announces $105 Million Private Placement Financing
February 12, 2025
From
Aligos Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
January 13, 2025
Via
Benzinga
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 13, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Present at Investor Conferences in December
November 26, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Presents Positive Data at The Liver Meeting (TLM) 2024
November 19, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
November 06, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024
October 30, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184
October 22, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024
October 15, 2024
Three abstracts accepted for poster presentations on ALG-000184 and ALG-055009
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 11, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Appoints David Perry as Vice President of Business Development
October 01, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics to Present at Investor Conferences in October
September 30, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
September 24, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH
September 19, 2024
From
Aligos Therapeutics
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
